FLAMMA Breaks Ground For New R&D Building In Italy
Flamma SpA (“Flamma”), a preeminent Contract Development and Manufacturing Organization (CDMO) that develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, is proud to announce the ground breaking for their new R&D building. While most CEOs use a gold plated shovel, Flamma’s CEO Gian Paolo Negrisoli, used an excavator to mark the groundbreaking of the new R&D Building at Flamma’s headquarters in Chignolo d’Isola, Bergamo, Italy.
This marks the expansion at Flamma’s headquarters that will allow Flamma to quadruple its R&D space. The R&D building will accommodate 50 additional employees providing additional R&D and analytical development laboratories as well as offices and meeting rooms. In addition to these features, there will be a lab for high containment and special chemistries.
During the Covid-19 crisis of 2020, our teams in Italy and China worked tirelessly to continue production of important molecules that are critical to help fight the virus. The Italian team hung a sign reading #MOLAMIA which means ‘Don’t Give Up’. Flamma doesn’t give up. This important milestone is another example of the commitment made to not only customers but employees to deliver a first class organization where people want to place their projects.
The new R&D building will serve as a complement the R&D work being done at Flamma USA in Malvern, PA outside of Philadelphia. The team in the USA continues to grow as more projects come on board.
View a one minute video here: https://vimeo.com/424568102
About Flamma:
FLAMMA is a family owned & run, fully integrated CMO based in Bergamo (near Milan in Northern Italy) established in 1950. FLAMMA is a company specialized in the cGMP manufacture of APIs, NCEs, RSMs, and advanced intermediates for the pharmaceutical industry. Flamma has particular expertise in high value chiral materials specifically amino acid related materials. Flamma also manufactures specialty compounds and advanced intermediates for the nutraceutical and cosmetic industries and has several generic products.
FLAMMA has four manufacturing facilities all with R&D labs- Italy (2), China, and the USA. Both cGMP Italian locations (Chignolo & Isso) are regularly inspected by the FDA and AIFA. Flamma Honkai, located in Dalian, China, has a new R&D building as well as a cGMP production plant. Flamma provides security when working in China with our 100% owned, self-managed facilities that deliver results without worry. Flamma reliably supplies materials directly to customers and/or delivers materials to its cGMP facilities in Italy in order to deliver the customer’s compound on-time and with the desired specifications. Flamma offers costeffective services to customers looking for a trusted partner within China.
The Malvern, PA site located outside Philadelphia provides Flamma with the ability to service customers looking to keep materials within the USA for pre-clinical/early stage clinical development as well as small scale commercial manufacturing.
Being a fully integrated company allows Flamma to move your compounds quickly along their journey taking into consideration all aspects necessary for the success of your project.
Flamma can be of assistance for early stage pre-clinical development of small molecules as well as for large-scale commercial manufacturing. With a total reactor capacity of 450 m3 and over 600 employees, see why Flamma should be your next contract manufacturer. FLAMMA - THE THINKING CDMO. For more information, visit www.flammagroup.com.
Source: Flamma SpA